1. Scrip
  2. >>Business
  3. >>Deals

GSK Takes Over J&J/Arrowhead Hep B Candidate For Combo Development

 
• By Joseph Haas

Deal Snapshot: Seeking to develop a combination regimen for chronic hepatitis B, GSK acquires rights to J&J/Arrowhead’s siRNA candidate JNJ-3839 to pair with its antisense candidate bepiroversen.

Transfer
An Arrowhead-discovered HBV candidate is going from J&J to GSK • Source: Shutterstock

Who: GSK/Johnson & Johnson/Arrowhead

What: GSK is assuming the rights to a Phase II siRNA candidate for hepatitis B that Arrowhead previously licensed to Johnson & Johnson for use in a combination regimen seeking...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business